Works matching IS 14752867 AND DT 2019 AND VI 19 AND IP 1

Results: 360
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12

    AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models.

    Published in:
    Cancer Cell International, 2019, v. 19, n. 1, p. 1, doi. 10.1186/s12935-019-1059-8
    By:
    • Shaw, Stephen M.;
    • Middleton, Jenny;
    • Wigglesworth, Kim;
    • Charlemagne, Amber;
    • Schulz, Oliver;
    • Glossop, Melanie S.;
    • Whalen, Giles F.;
    • Old, Robert;
    • Westby, Mike;
    • Pickford, Chris;
    • Tabakman, Rinat;
    • Carmi-Levy, Irit;
    • Vainstein, Abi;
    • Sorani, Ella;
    • Zur, Arik A.;
    • Kristian, Sascha A.
    Publication type:
    Article
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42

    S-15 in combination of Akt inhibitor promotes the expansion of CD45RA<sup>−</sup>CCR7<sup>+</sup> tumor infiltrating lymphocytes with high cytotoxic potential and downregulating PD-1<sup>+</sup>Tim-3<sup>+</sup> cells as well as regulatory T cells.

    Published in:
    Cancer Cell International, 2019, v. 19, n. 1, p. N.PAG, doi. 10.1186/s12935-019-1043-3
    By:
    • Xu, Benling;
    • Yuan, Long;
    • Chen, Guangyu;
    • Li, Tiepeng;
    • Zhou, Jinxue;
    • Zhang, Chengjuan;
    • Qin, Peng;
    • Muthana, Musleh M.;
    • Wang, Shengdian;
    • Du, Xuexiang;
    • Gao, Quanli
    Publication type:
    Article
    43
    44
    45
    46
    47
    48
    49
    50